PETE

Meet the 1,000th STAY participant: Winston! We've officially enrolled ONE THOUSAND DOGS in our LOY-002 lifespan extension study + we are upping enrollment to 1,300 dogs! this study will definitely quantify lifespan extension + quality of life improvement from our lead drug

💜 Noor. Good Job.

I really just want to talk to scientists about science

Doing a Podcast with Christine Von Raesfeld and Carolina Consuegra this morning! We gain so much knowledge on data generation, research and translation and don't share it enough. streamyard.com/c375ngsvvb

BridgeBio: Moneyball for Biotech centuryofbio.com/p/bridgebio New biomedical advances need to navigate "The Valley of Death" to get from research labs to the clinic: Every year, ~$50B goes into basic research* and >$100B into clinical development, but less than $10B goes into the *translational* work necessary to move findings from the lab to the clinic... This can create a disconnect between biomedical progress and clinical progress. There are now *thousands* of genetic diseases with known causes but no available treatments. In 2012, Andrew Lo, a brilliant MIT economist, proposed a solution. By creating a big diversified basket of translational programs, the risk profile could fundamentally change, making it possible to hyper-scale investment. For years, nothing came of this idea. But in 2015, Neil Kumar quit his job at Third Rock and took the entrepreneurial leap to test this theory. The company Kumar founded is called BridgeBio. In just ten years, BridgeBio has raised billions of dollars and launched over thirty drug programs, receiving eighteen INDs and *three* FDA drug approvals. I've spent months studying this company's complex experiment in accelerating biomedical progress with portfolio theory. You can read the full story of BridgeBio's journey—with many wild twists and turns—to make a new kind of pharma organization for patients with genetic disease at CoB.

Nice work.

Excited to announce our graduate course AI in Medicine 2 this Spring @HarvardDBMI @harvardmed Course syllabus zitniklab.hms.harvard.edu/AIM2 The syllabus features weekly lectures, focused tutorials on cutting-edge AI topics, hands-on student research projects, and weekly quizzes personalized for each student. We will share materials publicly throughout the course We will explore: 🔍 Self-supervised learning 🎨 Generative models 🔗 Multimodal techniques 🤖 Agentic pipelines Applications span NLP, medical imaging, relational and molecular learning, and longitudinal patient data Course staff: @YEktefaie @YepHuang @c_sheare Grey Kuling @AIM_Harvard_PhD @BIG_Harvard_PhD @harvard_data @KempnerInst @broadinstitute

Biohacking isn't fighting the limits of biology it's fighting the limits of our imagination

Yes. The healthcare system is not set up to support real personalized medicine. Healthcare economic infra of lowest common denominator / bell curve medicine is fundamentally incompatible with what we can do in the data / tech / bio sphere for personalized medicine.

The Rare As One Network is now nearly 100 patient-led organizations strong. Our impact report summarizes some of the key successes & lessons learned from our first cohort on how to cultivate synergies through this incubation-style research program czi.co/3ZRgXSo

this is a long read, but i had some time to think over dinner and wanted to share a few thoughts and provide a plan forward: 0. i’ve had a lot of very memorable days on the internet over the past 30 years, but this one tops them all. my wife yi and i are unbelievably grateful to the SOL community. as a reminder - 100% of every penny we've made from this, across every kitkat/memecoin, including LP fees will be going directly to rare disease research (minus any tax obligations). i will work on a way to verify this commitment transparently with the community in the form of donation receipts. thankfully the chain is already publicly auditable. 1. a lot people seem very upset that early traders made a lot of money off of $MIRA. i don't get this at all. they made a good investment early, and got rewarded for it. good on them. when we originally started our gofundme, we were hoping to contribute maybe $2-300K or so beyond what we donated early this year to hankinson lab for christmas. now, even if we don't sell a single token more, we're going to send them at least $1M this christmas. that's INCREDIBLE - and it makes such a huge difference. the reality is if those early people didn't make these moves, the lab would be worse off. providing more funding for research is the only thing that matters to me here, full stop. how much degens make or lose money in the pvp trenches of pump is not something that is any of my business. if you made a lot of money, i'm genuinely happy for you - but please consider donating some of your profits to hankinson lab., if you lost a lot of money, i’m very sorry - but magic internet money is magic internet money. 2. at least a few crazies in mentions think that i was somehow on the “inside” and this entire thing has been some kind of conspiracy - if you're one of them, i just don’t know what to tell you. i have a day job and it is not degening magic internet money. i run a company funded by a16z called runway.com, and we work on non-crypto finance software for cfos. nowdays, by night i do deep research into craniopharyngiomas and related brain tumors. i literally didn’t have a personal SOL address until yesterday. crypto wasn’t even a payment option outside of gofundme until folks asked me for one, and when i gave them one it was my ENS. the idea that i would have the time and even know how to do something like this is wildly unbelievable. 3. i am not elon - between running a growing startup, dealing with my daughter’s medical condition, and other obligations, i simply don’t have the bandwidth to manage a crypto anything. so my constraints on a path forward are: 1) to maximize support to rare disease research by providing predictability / trust 2) to do so in the most transparent way possible that helps me sleep well at night 3) to do it in a way that doesn’t take very much of my time to manage. so here’s the plan: starting in about 12 hours, i will be liquidating $1,000 worth of $MIRA every 10 minutes, perpetually. no more and no less than that. if i change this schedule, i commit to announcing it 24 hours in advance. if you want to rug it to $0, go for it - at the end of the day we set out to raise $200K and we will end up with at least $1M towards rare disease research. no matter what, this has been a win for the world. but if it moons, then hankinson lab will get the SOL’s community support for much longer, and that really makes a big difference. so that’s it! hope that's all pretty simple and reasonable. yi, mira and i are so unbelievably grateful to you all - each and every one of you. christmas magic was made real this year thanks to all of you. forever grateful.

I just joined @getairchat! Thanks @phoebeyao for the invite. Maybe I'll start posting more. Follow me here: air.chat/pete./

@MTomasson @eperlste What happens when standard of care options are exhausted? We've seen patients cycled back on to drugs that oncologists know are not going to produce a durable response.. which, to us seems like a great time to start looking for better options.

@eperlste We know what we’re doing? First thing that came to mind. 😂 Note bene: second nature, no, but first huge successes were repurposed drugs: thalidomide and bortezomib. First used in clinical trials.

Drug repurposing question for doctors: If you had a patient with a rare disease and they came to you with data supporting a new use for an approved drug, would you prescribe it off label? If not, why? Liability concerns? Bioethical concerns? Need for FDA or IRB oversight?

Honored to host George Church, PhD - Professor of Genetics at Harvard Medical School & pioneer in genomics on ep2 of pod! "I think the trend is going to be towards everybody getting IVF as the main way of having babies. I think that's a plausible future." @geochurch

Exciting news from @OrchidInc! Today, we're announcing the world's first whole genome embryo reports. This is a massive upgrade – 100x the amount of data – and a major leap in reproductive tech. And the best part, it's now available at IVF centers across the nation.

I am so proud of this work and hope you will join us!